Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safest dose of MORAb-003 in subjects with
advanced ovarian cancer. MORAb-003 is an antibody directed to an antigen on the surface of
ovarian cancer cells.